Mycophenolic acid upregulates miR-142-3P/5P and miR-146a in lupus CD4 + T cells

Abstract

Background

Mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil (MMF), is a noncompetitive inhibitor of inosine monophosphate dehydrogenase, and is now widely used for the treatment of systemic lupus erythematosus (SLE). Dysregulated expression of microRNA has been reported to be associated with the pathogenesis of SLE. However, it is unexplored whether altering microRNA expression in SLE patients is one of the therapeutic effects of MPA.

Objectives

This study thus aims to investigate the effect of MPA on microRNAs expression in lupus CD4⁺T cells and its underlying mechanisms.

Results

According to our microarray data, 101 upregulated microRNAs and 77 downregulated microRNAs were identified in MPA-treated lupus CD4⁺T cells. Among these microRNAs, miR-142-3p/5p and miR-146a expression was found to be significantly increased in MPA-treated lupus CD4⁺T cells compared to untreated controls. Furthermore, we observed that MPA-treated CD4⁺T cells from patients with SLE showed enriched levels of H4 acetylation in the putative miRNA-142 regulatory region and enhanced levels of H3 acetylation in the putative miRNA-146a regulatory region compared to untreated cells.

Conclusion

Data from this study suggest that MPA activates miR-142 and miR-146a expression through histone modification at the promoter region, which may partially explain the pharmacological mechanisms of MPA for SLE.

Keywords

Systemic lupus erythematosus mycophenolic acid microRNAs

Get full access to this article

View all access options for this article.

References

Tsokos

. Systemic lupus erythematosus. N Engl J Med 2011; 365: 2110–2121.

Hewagama

Richardson

. The genetics and epigenetics of autoimmune diseases. J Autoimmun 2009; 33: 3–11.

Zhang

Zhao

Sawalha

Richardson

. Impaired DNA methylation and its mechanisms in CD4(+)T cells of systemic lupus erythematosus. J Autoimmun 2013; 41: 92–99.

Jonsson

Carlsten

. Mycophenolic acid inhibits inosine 5'-monophosphate dehydrogenase and suppresses production of pro-inflammatory cytokines, nitric oxide, and LDH in macrophages. Cell Immunol 2002; 216: 93–101.

Iaccarino

Rampudda

Canova

Della

Sarzi-Puttinic

Doria

. Mycophenolate mofetil: What is its place in the treatment of autoimmune rheumatic diseases? Autoimmun Rev 2007; 6: 190–195.

Liu

Jiang

Wang

Yao

. Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: A meta-analysis of randomized controlled trials. Drugs 2012; 72: 1521–1533.

Dooley

Jayne

Ginzler

. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365: 1886–1895.

Wang

. Mycophenolic acid inhibits SLE-associated cytokine expression and promotes apoptosis of peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Acta Pharmacol Sin 2006; 27: 1051–1057.

Bartel

. MicroRNAs: Genomics biogenesis, mechanism, and function. Cell 2004; 116: 281–297.

10.

Kang

Liu

. MicroRNAs of the miR-17 approximately 92 family are critical regulators of T(FH) differentiation. Nat Immunol 2013; 14: 849–857.

11.

Baltimore

Boldin

O'Connell

Rao

Taganov

. MicroRNAs: New regulators of immune cell development and function. Nat Immunol 2008; 9: 839–845.

12.

Chau

Ebert

. MiR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 2007; 129: 147–161.

13.

Ceribelli

Yao

Dominguez-Gutierrez

Nahid

Satoh

Chan

. MicroRNAs in systemic rheumatic diseases. Arthritis Res Ther 2011; 13: 229.

14.

Zhao

Wang

Liang

. MicroRNA-126 regulates DNA methylation in CD4 + T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. Arthritis Rheum 2011; 63: 1376–1386.

15.

Tang

Luo

Cui

. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 2009; 60: 1065–1075.

16.

Zhou

Haupt

Prots

. MiR-142-3p is involved in CD25 + CD4 T cell proliferation by targeting the expression of glycoprotein A repetitions predominant. J Immunol 2013; 190: 6579–6588.

17.

. MiR-142-3p regulates the formation and differentiation of hematopoietic stem cells in vertebrates. Cell Res 2013; 23: 1356–1368.

18.

Sun

Shen

Yang

Zhu

. MiR-223 and miR-142 attenuate hematopoietic cell proliferation, and miR-223 positively regulates miR-142 through LMO2 isoforms and CEBP-beta. Cell Res 2010; 20: 1158–1169.

19.

Ding

Liang

Zhao

. Decreased microRNA-142-3p/5p expression causes CD4 + T cell activation and B cell hyperstimulation in systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2953–2963.

20.

Yang

Boldin

. MiR-146a controls the resolution of T cell responses in mice. J Exp Med 2012; 209: 1655–1670.

21.

Tan

Cohen

Fries

. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.

22.

Zhao

Liu

Liang

. E4BP4 overexpression: A protective mechanism in CD4 + T cells from SLE patients. J Autoimmun 2013; 41: 152–160.

23.

Crispin

Kyttaris

Terhorst

Tsokos

. T cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010; 6: 317–325.

24.

Boldin

Taganov

Rao

. MiR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med 2011; 208: 1189–1201.

25.

Van den Hove

Kompotis

Lardenoije

. Epigenetically regulated microRNAs in Alzheimer's disease. Neurobiol Aging 2014; 35: 731–745.